Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy ; volume:8 ; number:1 ; day:6 ; month:11 ; year:2023 ; pages:1-26 ; date:12.2023
Signal transduction and targeted therapy ; 8, Heft 1 (6.11.2023), 1-26, 12.2023
- Creator
-
Wang, Zhi-Qiang
Zhang, Zhao-Cong
Wu, Yu-Yang
Pi, Ya-Nan
Lou, Sheng-Han
Liu, Tian-Bo
Lou, Ge
Yang, Chang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01647-6
- URN
-
urn:nbn:de:101:1-2024011708420909923571
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Zhi-Qiang
- Zhang, Zhao-Cong
- Wu, Yu-Yang
- Pi, Ya-Nan
- Lou, Sheng-Han
- Liu, Tian-Bo
- Lou, Ge
- Yang, Chang
- SpringerLink (Online service)
Other Objects (12)
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
Dissecting the role of BET bromodomain proteins BRD2 and BRD4 in human NK cell function
Investigating the role of BET bromodomain proteins for Ewing sarcoma specific expression profiles and malignancy
Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
Dissecting the role of BET bromodomain proteins BRD2 and BRD4 in human NK cell function
Investigating the role of BET bromodomain proteins for Ewing sarcoma specific expression profiles and malignancy
Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
Dissecting the role of BET bromodomain proteins BRD2 and BRD4 in human NK cell function
Investigating the role of BET bromodomain proteins for Ewing sarcoma specific expression profiles and malignancy
Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer